Asuragen to present innovations in fragile X testing at upcoming American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Austin, Texas – March 24, 2015 – Asuragen, Inc., a leading molecular diagnostics company and innovator in fragile X testing capabilities, will present at the upcoming American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, March 24-28, 2015 in Salt Lake City, UT. The Company will showcase its broad expertise in fragile X-related diagnostic products and development efforts in the areas of oncology, genetic testing and next-generation sequencing (NGS).
In conjunction with the ACMG Annual Clinical Genetics Meeting, Asuragen will host an Exhibit Theater presentation at 12:30 PM on Friday, March 27, 2015 in Exhibit Theater #1. Stephanie Sherman, Ph.D., Professor, Department of Human Genetics at Emory University School of Medicine will describe advances in our understanding of fragile X gene stability in a presentation titled, “Gene Interrupted: AGG ‘Bumps in the Road’ Refine Fragile X Risk Assessments.” This presentation will detail the significant impact that AGG sequencing analysis can have in individualizing the risk of triplet repeat expansion from fragile X carriers to their children.
Asuragen’s innovations in fragile X molecular profiling will also be featured in a scientific poster that demonstrates additional applications for the company’s core AmplideX® PCR technology. This poster is a collaboration with The Hospital for Sick Children in Toronto, and describes the evaluation of a novel set of FMR2 (FRAXE) PCR reagents compared to Southern blot analysis, including the identification of false positive Southern blot results that were reconciled using the AmplideX prototype PCR assay.
For more information on Asuragen’s activities at the ACMG Annual Clinical Genetics Meeting, visit booth #839.
Asuragen is a molecular diagnostics company driving better patient management in oncology and genetic disorders through best-in-class clinical testing solutions. The company uses a breadth of technologies and scientific talent to discover, develop and commercialize diagnostic products for clinical laboratories and for our Bio/Pharma partners. Asuragen’s development of innovative diagnostic products will help transform medicine by improving clinical outcomes and health economics. For more information, visit www.asuragen.com.
Lynne Hohlfeld SVP, Corporate Development and Chief Financial Officer